Bifogade filer
InterimReport Q1 ENG 250514
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
STOCKHOLM, SWEDEN – 14 May 2025: Modus Therapeutics Holding AB (“Modus Therapeutics”) hereby publishes an interim report for the first quarter of 2025. The report is available on the company’s website (www.modustx.com) and as an attachment to this release. Below is a summary of the interim report.
Clinical progress and strengthened trial infrastructure mark Q1 2025
Modus Therapeutics entered 2025 with sustained clinical momentum, achieving several key milestones in the development of sevuparin—its lead candidate targeting severe and underserved conditions such as anemia in chronic kidney disease (CKD), severe malaria, and sepsis. Patient enrollment was successfully completed in the Phase I SEVUSMART study in severe malaria, and the ongoing Phase IIa CKD-anemia trial progressed as planned, bolstered by the activation of a second study site in Italy. The company also secured bridge financing from its largest shareholder, Karolinska Development, highlighting continued confidence in its strategy and progress.
John Öhd, CEO of Modus Therapeutics, commented:
"The first quarter of 2025 underscores our commitment to advancing sevuparin for patients with urgent unmet needs. The successful completion of patient enrollment in our severe malaria study and the steady progress in our CKD-anemia trial are important steps forward. With strong support from our partners and shareholders, we are well-positioned to deliver meaningful innovation in global health."
The first quarter in figures
- The loss after tax amounted to TSEK 2 815 (3 105).
- The loss per share amounted to SEK 0,08 (0,09).
- The cash flow from current operations was negative in the amount of TSEK 4 059 (3 665).
Important events during the first quarter
- Modus Therapeutics receives a recruitment update from the collaborative SEVUSMART Phase 1b study in severe malaria.
- Modus Therapeutics announces completion of patient enrollment in the SEVUSMART Phase 1b study for severe malaria.
- Modus Therapeutics secures bridge financing from Karolinska Development.
Important events after the end of the period
- Modus Therapeutics to present preclinical data supporting sevuparin’s effects in chronic kidney disease at BioIron 2025.
- Modus Therapeutics opens second study site in ongoing Phase IIa CKD-anemia study.
CEO John Öhd will provide comments on the report in an interview with Jonathan Furelid on May 14 at 16:00.
Link to Interview: https://www.youtube.com/watch?v=5XIF4TVaJ9w